Reading NGNE? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track NGNE free→Reading NGNE? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track NGNE free→QuarterlyIQ Insights · NGNE
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition On May 12, 2026, Neurogene Inc. (the “Company”) issued a press release announcing financial results for the quarter ended March 31, 2026. A copy of the press release announcing such results is attached as Exhibit 99.1 to this Current Report on Form 8-K. Also on May 12, 2026, the Company posted an updated corporate presentation on its website. A copy of the corporate presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K. The…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers Effective as of April 20, 2026, the Board of Directors (the “Board”) of Neurogene Inc. (the “Company”), upon recommendation of the Board's Nominating and Corporate Governance Committee (the "Nominating Committee"), took action pursuant to the Company's Amended and Restated Bylaws to expand the Board to seven directors and appoint Christine Mikail, t…
Results of Operations and Financial Condition On March 24, 2026, Neurogene Inc. (the “Company”) issued a press release announcing financial results for the quarter and year ended December 31, 2025. A copy of the press release announcing such results is attached as Exhibit 99.1 to this Current Report on Form 8-K. Also on March 24, 2026, the Company posted an updated corporate presentation on its website. A copy of the corporate presentation is furnished as Exhibit 99.2 to this Current Report o…
Results of Operations and Financial Condition On November 13, 2025, Neurogene Inc. (the “Company”) issued a press release announcing financial results for the quarter ended September 30, 2025. A copy of the press release announcing such results is attached as Exhibit 99.1 to this Current Report on Form 8-K. Also on November 13, 2025, the Company posted an updated corporate presentation on its website. A copy of the corporate presentation is furnished as Exhibit 99.2 to this Current Report on…
Results of Operations and Financial Condition On August 11, 2025, Neurogene Inc. (the “Company”) issued a press release announcing financial results for the quarter ended June 30, 2025. A copy of the press release announcing such results is attached as Exhibit 99.1 to this Current Report on Form 8-K. Also on August 11, 2025, the Company posted an updated corporate presentation on its website. A copy of the corporate presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K.…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On June 12, 2025, Neurogene Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the Company's stockholders approved amendments to each of the Company's 2023 Equity Incentive Plan and the 2023 Employee Stock Purchase Plan to clarify that the number of outstanding shares of common stock used…
and Exhibit 99.1 attached hereto are being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information or Exhibit 99.1 be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference to such filing.
Entry Into a Material Agreement Amendment to Letter Agreement On April 14, 2025, Neurogene Inc. (the “ Company ”) entered into an amendment to the July 17, 2023 letter agreement between the Company and Baker Bros. Advisors LP and/or one or more of its affiliates (collectively, “ BBA ”), pursuant to which the parties agreed to increase the threshold at which BBA has certain rights to nominate one person for election as a director of the Company from a minimum of 12.5% of the Company’s then-out…
Results of Operations and Financial Condition On March 24, 2025, Neurogene Inc. (the “Company”) issued a press release announcing financial results for the quarter and year ended December 31, 2024. A copy of the press release announcing such results is attached as Exhibit 99.1 to this Current Report on Form 8-K. Also on March 24, 2025, the Company posted an updated corporate presentation on its website. A copy of the corporate presentation is furnished as Exhibit 99.2 to this Current Report o…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.